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Abstract
Objective: Atrial fibrillation is the commonest chronic arrhythmia and the etiology is widely varied. The 
aim of this study was to determine the etiology, clinical characteristics and treatment  offered to adult 
patients with atrial fibrillation managed in a referral hospital in Port Harcourt, southern Nigeria.
Methods: A retrospective study of all the patients  referred to the cardiology unit   or seen in the cardiac 
clinic with ECG evidence of atrial fibrillation over one year period July 2012 to June 2013 was carried out. 
Those with confirmed atrial fibrillation and had transthoracic echocardiographic evaluation were 
analyzed for the study. Clinical and demographic characteristics and treatment offered to the patients were 
obtained from their hospital notes. Stroke risk was retrospectively assessed  using the CHADS2 score.
Results: Sixty-eight patients comprising twenty nine females and thirty nine males [ratio of 1;1.3] had 
complete data . Age range was 30-87 years and mean age was 59.81±14.22 years. Mean blood pressures 
were 126.03± 26.89 mmHg systolic and  67.22± 18.60 mmHg diastolic. Hypertensive heart disease was 
the diagnosis in forty patients [58.82%], dilated cardiomyopathy in thirteen [19.2%], rheumatic heart 
disease in ten [14.71%], thyrotoxicosis in three [4.41%], one each due to endomyocardial fibrosis [EMF] 
and Cor pulmonale. Ten patients (14.71%) had valvular atrial fibrillation (AF) while most [ 85.29%] had 
non-valvular AF. None of the patients had evidence of stroke risk evaluation in their notes and less than 
10%  received anticoagulation treatment despite all the patients having moderate to high risk of stroke 
from our own CHADS2 evaluation. 
Conclusion: Hypertensive heart disease was the commonest cause of atrial fibrillation in patients seen 
Port Harcourt, Southern Nigeria, followed by dilated cardiomyopathy and rheumatic heart disease. Stroke 
risk evaluation was non-existent and adherence to guidelines in management of atrial fibrillation was sub-
optimal. 
Keywords: Atrial fibrillation, thrombosis, CHADS2 Score, stroke risk, hypertensive heart disease, 
cadiomyopathy.
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La fibrillation auriculaire: Une analyse de l'étiologie et le modèle de 
gestion dans un hôpital de soins tertiaires à Port-Harcourt, le sud du 
Nigeria
Akpa MR., Ofori S.
Résumé
Objectif: La fibrillation auriculaire est le plus fréquent d'arythmie chronique et l'étiologie est très varié. 
Le but de cette étude était de déterminer l'étiologie, les caractéristiques cliniques et les traitements offerts 
aux patients adultes atteints de fibrillation auriculaire gérée dans un hôpital de référence à Port Harcourt, 
au sud du Nigeria.
Méthodes: Une étude rétrospective de tous les patients référés à l'unité de cardiologie ou vu à la clinique 
cardiaque avec ECG preuves de la fibrillation auriculaire sur une période de l'année Juillet 2012 à Juin 
2013 a été réalisée. Ceux souffrant de fibrillation auriculaire et avait confirmé l'évaluation 
échocardiographique transthoracique ont été analysés pour l'étude. Caractéristiques et le traitement 
cliniques et démographiques offerts aux patients ont été obtenus à partir de leurs notes de l'hôpital. Le 
risque d'AVC a été évaluée rétrospectivement en utilisant le score CHADS2.
Résultats: Soixante-huit patients comprenant vingt-neuf femmes et neuf hommes [trente rapport de 1; 
1.3] disposaient de données complètes. Tranche d'âge était 30-87 ans et l'âge moyen était 59,81 ± 14,22 
années. Tensions moyennes étaient 126.03 ± 26,89 mmHg systolique et 67,22 ± 18,60 mmHg. 
Cardiopathie hypertensive était le diagnostic en quarante patients [58,82%], la cardiomyopathie dilatée 
dans treize [19,2%], la cardiopathie rhumatismale sur dix [14,71%], la thyréotoxicose sur trois [4,41%], 
un chacun en raison de la fibrose endomyocardique [EMF] et un cœur pulmonaire. Dix patients (14,71%) 
avaient fibrillation auriculaire valvulaire (AF) alors que la plupart [85.29%] avaient une FA non 
valvulaire. Aucun des patients avait des preuves de l'évaluation du risque d'AVC dans leur notesand moins 
de 10% ont reçu un traitement anticoagulant, malgré tous les patients ayant un risque modéré à élevé 
d'AVC à partir de notre propre évaluation CHADS2.
Conclusion: la maladie cardiaque hypertensive était la cause la plus fréquente de la fibrillation auriculaire 
chez les patients vus Port Harcourt, Nigeria du Sud, suivie cardiomyopathie bydilated et les cardiopathies 
rhumatismales. l'évaluation du risque d'AVC Les patients ont été pas gérés conformément aux lignes 
directrices recommandées.
Mots-clés: fibrillation auriculaire, la thrombose, CHADS2 score, risque d'AVC, cardiopathie 
hypertensive, cadiomyopathy.
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INTRODUCTION
Atrial fibrillation (AF) remains the most 
common sustained cardiac arrhythmia (1). It 
s u b s t a n t i a l l y  i n c r e a s e s  t h e  r i s k  o f  
thromboembolism, stroke as well as heart failure 
thus interfering with the length and quality of life 
of those affected (1). Its prevalence increases 
with age. In developed nations of the world the 
overall prevalence is estimated at 1.5-2% of the 
general population and the average age group 
affected  are individuals aged between 75 and 85 
years of age and in this group, prevalence may be 
up to 9% (2). In these countries Atrial fibrillation 
is commoner in whites than in blacks, males are 
more frequently affected than females and 
majority of all cases are due to cardiovascular 
diseases such as coronary artery disease [CAD], 
hypertension, heart failure [CHF], diabetes and 
other conditions such asobesity and smoking 
with CAD and CHF as the commonest etiology 
(3,4).
In developing countries, AF is a growing 
public health problem due to the epidemiologic 
transition from communicable to non-
communicable diseases. However in contrast to 
findings in the developed countries, African 
s t u d i e s  s h o w e d  t h a t  h y p e r t e n s i o n ,  
cardiomyopathies and valvular heart diseases 
were  the commonest etiologies of atrial 
fibrillation (5,6,7). 
Various professional guidelines 
recognize the need for and have recommended 
strategies to characterize the risk of 
thromboembolism and stroke from AF in order to 
reduce the morbidity and mortality associated 
with this disorder (2,7). However, despite the 
availability of regularly updated guidelines from 
various societies, the management of atrial 
fibrillation is sub-optimal in Nigeria and other 
parts of sub-Saharan Africa. 
We hypothesized that evidence based 
strategies to prevent stroke may not be  optimally 
implemented in a high risk population with AF.  
This study was aimed at determining the pattern 
of structural heart disease and treatment offered 
to patients presenting with atrial fibrillation in a 
referral hospital in Port Harcourt, Southern 
Nigeria. 
MATERIALS AND METHODS
Study design and population: This was 
a retrospective analysis of patients' case records. 
All patients presenting to the cardiology unit of 
the internal medicine department of the 
university of Port Harcourt Teaching hospital 
over the period of July 2012 to June 2013 were 
identified. This hospital is a 600-bed tertiary 
hospital in Rivers State and receives referrals 
from within the state and neighboring states the 
South-South and South-East of Nigeria. The 
inclusion criteria were (i) all adults above the age 
of 18 years with atrial fibrillation  confirmed by a 
resting ECG and (ii) those patients with good 
quality echocardiograms.
ECG was performed with a six channel 
Rtwelve lead GE Cardiovit  machine from the 
ECG laboratory and was interpreted by two 
clinicians with expertise in identifying rhythm 
disturbance. Echocardiography to detect 
underlying  heart disease was carried out using 
ALOKA SSD 4000 machine with a 2.5MHz 
probe. The transthoracic echocardiographic 
procedures were done in the left lateral decubitus 
position and measurements were based on the 
American College of Cardiology ACC 
guidelines. We used the CHADS2 score (Refer 
Appendix 1) to stratify the stroke risk and we 
evaluated the type of treatment patients received 
as documented in their  clinical notes. 
Statistical analysis
Data was analyzed using Statistical 
Package for Social Sciences (SPSS) version 21.0. 
Results are presented in tables and graphs and 
expressed as mean ± standard deviation for 
continuous variables and proportions or 
percentages for categorical variables. t-tests and 
chi-square tests were used when appropriate to 
compare continuous and categorical variables 
respectively. A P value of less than 0.05 was 
considered statistically significant.
Ethical Approval: This was a retrospective 
analysis and did not require ethical approval, as 
patients were not contacted. The data were 
blinded and stored in a password-protected 
computer. Only the investigators had access to 
the data.
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RESULTS
Patients Demographics: Two hundred and 
twenty eight patients referred to the cardiology  
outpatient clinic for the first time were identified. 
Of these, sixty-eight patients had atrial 
fibrillation confirmed on ECG giving a 
prevalence rate of AF among general population 
referred for cardiology consultation of 29.8% 
Table 1 shows the clinical characteristics of the 
patients with documented AF.
Treatment of Atrial Fibrillation: Review of the 
case notes showed that the AF was not classified 
in any of the patients. The main symptom 
recorded was palpitation and average duration of 
symptoms was 10.8 weeks (range 3-68 weeks). 
Sixty-six patients received low dose [75mg] 
aspirin, 63 received digoxin, 6 received warfarin 
and four 4 received Amiodarone. Fifty-eight 
patients received digoxin and low dose Aspirin, 6 
patients received a combination of low dose 
aspirin, digoxin and warfarin and four patients 
received digoxin and Amiodarone (Ref. table 2)
Analysis of Stroke Risk: Review of the clinical 
case notes showed none of the patients had 
documented stroke risk evaluation by the 
attending physicians. Retrospective analysis for 
Stroke risk using the CHADS2 score showed that 
27 patients (39.71%) had intermediate risk for 
stroke (CHADS2 = 1) while 41 patients (60.29%) 
had high risk of  stroke (CHADS2 > 2) (Ref. table 
3)
                                                           
DISCUSSION
This study showed that males were more 
affected than females by AF. The mean age in this 
study was 59.81 years showing that atrial 
fibrillation occur in younger age groups in 
Nigerians generally compared with Caucasians 
in which the mean age in AF patients is higher 
than 70 [73.1]years (4). We opine that this is 
probably due to longer average life span, more 
than 60 years in most developed countries of 
Europe compared with less than 50 years in most 
African countries and better socioeconomic 
circumstances. 
We found hypertensive heart disease, 
dilated cardiomyopathies and rheumatic heart 
disease as commonest associated cardiac 
conditions in individuals with atrial fibrillation. 
This is in keeping with similar findings from 
other parts of Nigeria, Senegal and Cameroun 
(5,6,7) and in contrast to findings among 
Caucasians in whom coronary artery disease, 
congestive heart failure and obesity predominate 
(3,4). 
The CHADS2 score analysis carried out 
in the patients show that 60.3% of the patients had 
scores of 2 or more and had a high risk of stroke 
and is lower than found in Cameroonian patients 
60.3% Vs 91.9% (7). The highest risk was found 
in those aged over 70 years amongst whom 
89.5% had high risk of stroke. The analysis also 
showed increasing stroke risk with increasing age 
but this is not unexpected as stroke is generally 
commoner in the older age group. 
The main aim of treatment in atrial 
fibrillation is to prevent  the most severe known 
complications which is stroke and other 
thromboembolic phenomenon. Warfarin is the 
recommended drug of choice for thrombo 
prophylaxis in valvular and non-valvular AF 
while the newer agents are recommended for use 
only INR non-valvular AF (8,9,10,11). Our 
analysis of the treatment pattern however showed 
that whereas almost all the patients (94.11%) 
received anti platelet prophylaxis, only 8.8% 
received anticoagulation prophylaxis (warfarin) 
despite the majority being at sufficiently high risk 
for stroke. This low level of OAC use is much 
lower than the 34.2% reported from Cameroon, 
(7) 67% and 86% from the developed countries 
and 38% from Zimbabwe (12). This poor or low 
level use of OAC exposes the patients to 
avoidable thromboembolic events and we 
surmise that this may be due to  knowledge gap in 
the use of guidelines for the management of 
cardiac diseases by physicians as well as the 
challenge posed by paucity of facilities for 
monitoring warfarin use in the hospital. The 
emergence of the novel oral anticoagulants may 
make physicians more likely to place patients on 
these agents as the need for lifestyle and diet 
modification as well as the need for frequent 
(often unavailable and expensive) INR 
monitoring related to warfarin therapy is 
obviated with their use. However the high cost of 
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these agents may further limit their use  at the  
current time until cheaper generic forms become 
available.
Study limitations: We acknowledge that the 
retrospective nature of this study resulted in 
invariable missing data, which may have affected 
the quality of the analysis. In addition these 
patients were recruited from a cardiology clinic 
and thus the prevalence of AF and the treatment 
pattern may not represent the general population. 
However given that these rather inconclusive  
results were obtained from a teaching hospital, 
we surmise that it most likely underestimates the 
true magnitude of the problem.
CONCLUSION 
The prevalence of atrial fibrillation 
among patients referred to general cardiology 
clinics is high. The etiology of atrial fibrillation in 
Port Harcourt is similar to findings in other 
African patients but the atrial fibrillation was not 
classified and stroke risk not evaluated in any of 
the patients' records assessed. A large proportion 
of patients had moderate or high risk of stroke. 
Adherence to and implementation of available 
treatment guidelines appears low and pose 
significant hindrance to good patient 
management and improvement in morbidity and 
mortality.
RECOMMENDATIONS
This study highlights the poor focus on AF 
despite its increasing prevalence among the 
cardiology population. it also highlights poor 
adherence to evidence based guidelines on stroke 
risk management. We therefore recommend the 
following:
1. More attention should be paid to the 
proper evaluation of patient presenting 
with AF.
2. Enhance uptake of the guidelines on AF 
management by physicians involved in the 
care of these patient.
3. Increased availability of INR monitoring.
Conflict of interest: The authors declare no 
conflict of interest. 
 REFERENCES
1. Benjamin EJ, Wolf PA, DAgostino RB, 
Sibbershatz H, Kannel WB, and Levy D. Impact 
of Atrial Fibrillation on risk of death: The 
Framingham hear t  s tudy.  Ci rcula t ion  
1998;98(10):946-52. 
2. Kirchhof  P, Auricchio A, Bax J, Crijins A, Camm 
J, Diener HC, et al. Outcome parameters for trials 
in atrial fibrillation; executive summary. 
Recommendation from a concensus conference 
organized by the German Atrial Fibrillation 
Competence Network (AFNET) and the 
European Heart Rhythm Association (EHRA). 
Eur Heart J 2007;28:2803-2817.
3. Lip GY, Golding DJ, Nazir M, Beavas DG, Child 
DL, Fletcher RI. A survey of Atrial fibrillation in 
general practice: The West Birmingham Atrial 
Fibrillation Project. Br J Gen Practice 1997;47: 
28. 
4. Thomas Cooke, Antje Groth, Sabrins Mueller, 
Mathias Pfannkuche, Frank Verheyen, Roland 
Linder, et al. Incidence and prevalence of Atrial 
Fibrillation: An analysis based on 8.3million 
patients. Europace 2013;15(4): 486-493.
5. Mbakwem AC, Ajuluchukwu JNA, Oke DA. 
C l i n i c a l ,  E l e c t r o c a r d i o g r a p h i c  a n d  
Echocardiographic features of Atrial fibrillation 
in Nigerians: An Analysis of 39 patients seen at 
the University of Lagos Teaching Hospital. 
Nigerian Quarterly J Hosp Med 2002;12(1-4)29-
33.
6. Massane Mbaye, Soulemane Pessinaa, Malick 
Bodian, Bamba N. Moutamadon, Faton Mbaye, 
Adama Kane et al. Atrial fibrillation, frequency, 
etiologic factors, evolution and treatment in a 
cardiology department in Dakar, Senegal. Pan Afr 
Med J 2010;6:16. 
7. Marie Ntep-Gweth, Marc Zimmermann, 
Alexandre Meiltz, Samuel Kingue, Piere Ndobo, 
Philip Urban, ? et al. Atrial Fibrillation in Africa: 
Clinical Characteristics, Prognosis, and 
adherence to guidelinesin Cameroon. Europace 
2010; 12: 482-487.
8. Friberg L, Hamman N, Ringh M, Petterson H, 
Rosenqvist M. Stroke prophylaxis in Atrial 
fibrillation: who gets it and who does not? Eur 
Heart J 2006;27:1954-64.
9. Lip GY, Edwards SJ. Stroke prevention with 
aspirin, warfarin and ximelagatran in patients 
Atrial Fibrillation, treatment                                                                                 Akpa and Ofori
Res. J. of Health Sci. Vol 3(4), October/December 2015                                         307
with non-valvular atrial fibrillation: a systematic 
review and meta-analysis. Thromb Res 2006; 
118:321–33.
10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: 
antithrombotic therapy to   prevent stroke in 
patients who have non valvular atrial fibrillation. 
Ann Intern Med 2007; 146: 857–67.
11. Mant J, Hobbs FD, Fletcher K, Roalfe A, 
Fitzmaurice D, Lip GY AND Murray E.. Warfarin 
versus aspirin for stroke prevention in an elderly 
community population with atrial fibrillation (the 
Birmingham Atrial Fibrillation Treatment of the 
Aged Study, BAFTA): a randomised controlled 
trial. Lancet 2007;370: 493–503.
12. Bhagat K, Tisocki K. Prescribing patterns for the 
use of antithrombotics in the management of atrial 




C= Congestive heart failure   Score of 1
H = Hypertension                   Score of 1
A = Age >75yrs                       Score of 1
D = Diabetes mellitus           Score of 1
S = Stroke or previous  TIA  Score of 2
Score Stroke Risks
0 =                   low risk
1 =                   intermediate risk
2 or more =         high risk
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Endomyocardial fibrosis  1 (1.5)  
Cor pulmonale 1 (1.5)  
 
Atrial Fibrillation, treatment                                                                                 Akpa and Ofori
Res. J. of Health Sci. Vol 3(4), October/December 2015                                         309
  



























































































Atrial Fibrillation, treatment                                                                                 Akpa and Ofori
Res. J. of Health Sci. Vol 3(4), October/December 2015                                         310
